Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio, Blue Sky Collaborate on Kinase Assay Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cisbio Bioassays and Blue Sky BioProducts today announced a partnership combining their technologies for the development of assays for target kinases.

The partnership will combine Cisbio's homogenous time resolved fluorescence technology, or HTRF, with Blue Sky's TDA 2.0 technology. TDA 2.0 is a stable solution of lipid-based nanoparticles with nickel-chelating moieties and serves as a template for the assembly of purified His-tagged proteins normally associated with membranes, Cisbio said in a statement.

The deal is expected to result in assays with "unparalleled sensitivity for obtaining better biologically enhanced results on target kinases," Cisbio said.

"Through HTRF, Cisbio Bioassays has developed extensive expertise in the field of kinase enzyme screening tools," said François Degorce, director of marketing and communications for Cisbio. "The combination of these two proven technologies in this area allows us to provide an even more robust and efficient solution for studying these key therapeutic targets, particularly in oncology research."

Based in Worcester, Mass., Blue Sky provides contract research organization services to pharmaceutical firms.

Terms of the deal were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.